Vicinitas

About Vicinitas

Vicinitas Therapeutics, a biotechnology firm, was established in 2021 as a collaborative effort between Celgene, a Bristol Myers Squibb company, and the Novartis Institutes for BioMedical Research (NIBR). The company launched with a substantial $65 million Series A financing round, co-led by a syndicate of prominent investors including Andreessen Horowitz, Deerfield Management, and founding partners Celgene and Novartis. This initial funding was aimed at advancing the company's proprietary platform for targeted protein stabilization.

The company's scientific foundation is built upon the pioneering research of its scientific co-founders, Dr. Daniel K. Nomura and Dr. James A. Wells. Dr. Nomura, a professor at the University of California, Berkeley, brings extensive expertise in chemical biology and proteomics. His laboratory has been at the forefront of developing chemoproteomic platforms to discover and functionally annotate proteins, with a focus on identifying novel therapeutic targets. Dr. Wells, a professor at the University of California, San Francisco, is a distinguished figure in protein engineering and has a track record of translating academic research into therapeutic applications. Their collective research into deubiquitinases (DUBs), enzymes that counteract protein degradation, underpins the company's core technology.

Vicinitas Therapeutics operates within the targeted protein modulation space, a competitive segment of the biotechnology market. The company is developing a novel class of medicines known as Deubiquitinase Targeting Chimeras (DUBTACs). This platform is designed to selectively and potently stabilize proteins that are otherwise degraded, a mechanism implicated in various diseases. The DUBTAC technology works by hijacking the body's natural deubiquitinase machinery to rescue specific proteins from degradation. This approach contrasts with the more common strategy of targeted protein degradation, offering a potential therapeutic avenue for diseases caused by protein insufficiency, such as certain cancers and genetic disorders.

The business model is centered on the research and development of a pipeline of DUBTAC-based therapeutics. The primary objective is to progress these novel drug candidates through preclinical and clinical trials to demonstrate safety and efficacy. The company's strategy involves leveraging its proprietary platform to create a portfolio of assets that could address a wide range of diseases currently lacking effective treatments. The ultimate goal is to bring these therapies to market, either independently or through strategic partnerships with larger pharmaceutical companies.